Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.23 USD | +0.31% | +4.19% | -22.07% |
Business Summary
Number of employees: 54
Managers
Managers | Title | Age | Since |
---|---|---|---|
Doug Onsi
CEO | Chief Executive Officer | 55 | 10-12-31 |
Chris Mirabelli
CHM | Chairman | 69 | 10-12-31 |
Jason Baum
CTO | Chief Tech/Sci/R&D Officer | 45 | 20-08-23 |
Michael Haas
CTO | Chief Tech/Sci/R&D Officer | - | - |
Cynthia Sirard
CTO | Chief Tech/Sci/R&D Officer | 54 | 11-12-31 |
Augustine Lawlor
COO | Chief Operating Officer | 67 | 15-12-31 |
General Counsel | 56 | 20-08-23 | |
Jonathan Miller
PRN | Corporate Officer/Principal | - | 19-12-31 |
Mark O’Mahony
PRN | Corporate Officer/Principal | 53 | 10-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Loscalzo
BRD | Director/Board Member | 72 | 15-12-31 |
Nissim Mashiach
BRD | Director/Board Member | 63 | 16-12-31 |
Chris Mirabelli
CHM | Chairman | 69 | 10-12-31 |
James Cavanaugh
BRD | Director/Board Member | 87 | 15-12-31 |
Thomas Dietz
BRD | Director/Board Member | 60 | 15-12-31 |
Doug Onsi
CEO | Chief Executive Officer | 55 | 10-12-31 |
Chris Richard
BRD | Director/Board Member | 54 | 23-01-16 |
Patricia Martin
BRD | Director/Board Member | 63 | 22-12-31 |
Richard Schilsky
BRD | Director/Board Member | 73 | 22-08-31 |
William Li
BRD | Director/Board Member | 61 | 16-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 38,264,464 | 32,143,071 ( 84.00 %) | 0 | 84.00 % |
Company contact information
Leap Therapeutics, Inc.
47 Thorndike Street Suite B1-1
02141, Cambridge
+617 714 0360
http://www.leaptx.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.07% | 123M | |
+9.76% | 106B | |
+1.65% | 104B | |
+6.72% | 23.25B | |
-13.20% | 22.5B | |
-6.64% | 18.7B | |
-37.08% | 17.95B | |
-11.22% | 16.99B | |
+7.89% | 14.26B | |
+40.51% | 12.76B |
- Stock Market
- Equities
- LPTX Stock
- Company Leap Therapeutics, Inc.